Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
MEDI7247 is an anti-ASCT2 ADC carrying a PBD payload that has completed a phase I trial in patients with various solid tumors, including mCRPC
Clinic-grade TB-500 from a licensed 503A compounding pharmacy carries a significantly lower risk profile than unregulated sources
Lancet 348 , 10791082 (1996)
Simultaneously, some tumor cells, owing to specific mutations, elevated ROS levels and other unique biological features, exhibit ferroptosis susceptibility, with their survival hinging on the ferroptosis defense system (108)
US$ 25.50
US$ 29.38
US$ 25.16
US$ 22.68
US$ 26.59
US$ 24.58
US$ 21.93
